Dapagliflozin: A Review in Symptomatic Heart Failure with Reduced Ejection Fraction.

ABSTRACT: Dapagliflozin [Farxiga^® (USA); Forxiga^® (EU)], a sodium-glucose cotransporter 2 (SGLT2) inhibitor, was recently approved in the USA and the EU for the treatment of adults with symptomatic heart failure with reduced ejection fraction (HFrEF). The cardiovascular (CV) benefits of dapagliflozin were first observed in the DECLARE-TIMI 58 trial, in which dapagliflozin 10 mg/day significantly reduced the risk of CV death or hospitalization for HF in patients with type 2 diabetes mellitus (T2DM) who had or were at risk for atherosclerotic CV disease. In the subsequent DAPA-HF trial, dapagliflozin 10 mg/day in addition to standard of care was associated with a significantly lower risk of worsening HF or CV death than placebo in patients with HFrEF, regardless of the presence o

SUBMITTER: Blair HA 

PROVIDER: S-EPMC8639555 | biostudies-literature | 2021 Nov

REPOSITORIES: biostudies-literature